Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: Timing, Severity, and Implications for HIV-TB Programs

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 4, 2014, Pages 423-428

  Luetkemeyer, Anne F ^a   Kendall, Michelle A ^b   Nyirenda, Mulinda ^c   Wu, Xingye ^b   Ive, Prudence ^d   Benson, Constance A ^e   Andersen, Janet W ^b   Swindells, Susan ^f   Sanne, Ian M ^d   Havlir, Diane V ^a   Kumwenda, Johnstone ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF MALAWI   (Malawi)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

HIV AIDS; Immune reconstitution inflammatory syndrome; Paradoxical reaction; Tuberculosis

Indexed keywords

CD4 ANTIGEN; CORTICOSTEROID; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RIFAMYCIN; STEROID; TENOFOVIR DISOPROXIL;

ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; DEATH; DISEASE SEVERITY; FEMALE; FISHER EXACT TEST; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LOG RANK TEST; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RANDOMIZATION; RANK SUM TEST; REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TUBERCULOSIS;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TUBERCULOSIS;

EID: 84898005626     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000030     Document Type: Review

References (17)

1. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362: 697-706
2. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482-1491
3. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1481
4. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011; 365:1492-1501
5. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516-523
6. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: Incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007;21:335-341
7. Haddow LJ, Moosa MY, Mosam A, et al. Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa. PLoS One. 2012;7:e40623
8. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516-523
9. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958;53:457-481
10. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34: 187-220
11. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509
12. Emdin CA, Millson P. A systematic review evaluating the impact of task shifting on access to antiretroviral therapy in sub-Saharan Africa. Afr Health Sci. 2012;12:318-324
13. Meintjes G, Rangaka MX, Maartens G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis. 2009;48:667-676
14. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1481
15. Laureillard D, Marcy O, Madec Y, et al. Paradoxical tuberculosisassociated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in the camelia randomized. AIDS. 2013; 27:2577-2586
16. Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: Findings from the SAPiT trial. Ann Intern Med. 2012;157:313-324
17. Meintjes G, Rabie H, Wilkinson RJ, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med. 2009;30:797-810